Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer

被引:3
作者
Kobayashi M. [1 ]
Matsui K. [1 ]
Hirashima T. [1 ]
Nitta T. [1 ]
Sasada S. [1 ]
Tada T. [2 ,3 ]
Minakuchi K. [2 ]
Furukawa M. [1 ,4 ]
Ogata Y. [1 ,4 ]
Kawase I. [1 ,4 ]
机构
[1] Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Osaka 583-8588
[2] Department of Radiology, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka
[3] Department of Radiology, Osaka City University Graduate School of Medicine, Osaka
[4] Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka
关键词
Chemoradiotherapy; Cisplatin; Non-small-cell lung cancer; Vinorelbine;
D O I
10.1007/s10147-006-0574-5
中图分类号
学科分类号
摘要
Background. The combination of chemotherapy and thoracic radiation therapy (TRT) is considered as a standard treatment for locally advanced non-small-cell lung cancer (NSCLC). Although the frequent interaction of anticancer agents and irradiation may produce stronger radio-sensitizing effects, the daily administration of these agents is complicated. We therefore used weekly administration of these agents, and conducted a phase I study of weekly cisplatin, vinorelbine, and concurrent TRT. The purpose of this study was to identify the maximum tolerated dose (MTD), the dose-limiting toxicity (DLT), and the recommended dose of this treatment. Methods. Patients with locally advanced NSCLC were enrolled in this study. Both cisplatin and vinorelbine were given intravenously on a weekly schedule for 6 weeks, starting on the first day of TRT, i.e., on days 1, 8, 15, 22, 29, and 36. The total dose of TRT was 60∈Gy. The dose of cisplatin was fixed at 20∈mg/m2 per week. The starting dose of vinorelbine was 15∈mg/m2 per week (dose level 1). Results. Nine patients were enrolled in this study. All three patients at dose level 1 experienced DLTs. We decreased the dose of vinorelbine to 10∈mg/m2 per week (dose level 0). Two of the six patients at dose level 0 experienced DLTs. Therefore, dose level 1 was considered as the MTD, and dose level 0 as the recommended dose. The DLTs of this treatment were esophagitis, fatigue, infection, and hyponatremia. Conclusion. The recommended dose of cisplatin is 20∈mg/m2 per week and that of vinorelbine is 10∈mg/m2 per week with standard TRT. A phase II study of this treatment is warranted. © The Japan Society of Clinical Oncology 2006.
引用
收藏
页码:314 / 319
页数:5
相关论文
共 50 条
[41]   Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer [J].
Nobuyuki Yamamoto ;
Yasumasa Nishimura ;
Kazuhiko Nakagawa ;
Kaoru Matsui ;
Masahiro Fukuoka .
Cancer Chemotherapy and Pharmacology, 2006, 58 :285-291
[42]   Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer - A phase I study [J].
Gagel, Bernd ;
Piroth, Marc ;
Pinkawa, Michael ;
Reinartz, Patrick ;
Zimny, Michael ;
Fischedik, Karin ;
Stanzel, Sven ;
Breuer, Christian ;
Skobel, Eric ;
Asadpour, Branka ;
Schmachtenberg, Axel ;
Buell, Ulrich ;
Eble, Michael J. .
STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 (05) :263-269
[43]   Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study [J].
Gridelli, C ;
Guida, C ;
Barletta, E ;
Gatani, T ;
Fiore, F ;
Barzelloni, ML ;
Rossi, A ;
de Bellis, M ;
D'Aniello, R ;
Scognamiglio, F .
LUNG CANCER, 2000, 29 (02) :131-137
[44]   A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group [J].
Segawa, Y ;
Ueoka, H ;
Kiura, K ;
Kamei, H ;
Tabata, M ;
Sakae, K ;
Hiraki, Y ;
Kawahara, S ;
Eguchi, K ;
Hiraki, S ;
Harada, M .
BRITISH JOURNAL OF CANCER, 2000, 82 (01) :104-111
[45]   A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: A preliminary report from the Okayama Lung Cancer Study Group [J].
Segawa Y. ;
Ueoka H. ;
Kiura K. ;
Kamei H. ;
Tabata M. ;
Sakae K. ;
Hiraki Y. ;
Kawahara S. ;
Eguchi K. ;
Hiraki S. ;
Harada M. .
British Journal of Cancer, 2000, 82 (1) :104-111
[46]   Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study [J].
Lippe, P ;
Tummarello, D ;
Monterubbianesi, MC ;
Silva, RR ;
Giuliodori, L ;
Mari, D ;
Santo, A ;
Pasini, E ;
Cetto, GL ;
Rossi, D ;
Porfiri, E ;
Cascinu, S ;
Cellerino, R .
ANNALS OF ONCOLOGY, 1999, 10 (02) :217-221
[47]   Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) [J].
José Rodrigues Pereira ;
Sandro J Martins ;
Sueli M Nikaedo ;
Flora K Ikari .
BMC Cancer, 4
[48]   A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study) [J].
Tanzawa, Shigeru ;
Ushijima, Sunao ;
Shibata, Kazuhiko ;
Shibayama, Takuo ;
Bessho, Akihiro ;
Kaira, Kyoichi ;
Misumi, Toshihiro ;
Shiraishi, Kenshiro ;
Matsutani, Noriyuki ;
Tanaka, Hisashi ;
Inaba, Megumi ;
Haruyama, Terunobu ;
Nakamura, Junya ;
Kishikawa, Takayuki ;
Nakashima, Masanao ;
Iwasa, Keiichi ;
Fujiwara, Keiichi ;
Kohyama, Tadashi ;
Kuyama, Shoichi ;
Miyazawa, Naoki ;
Nakamura, Tomomi ;
Miyawaki, Hiroshi ;
Ishida, Hiroo ;
Oda, Naohiro ;
Ishikawa, Nobuhisa ;
Morinaga, Ryotaro ;
Kusaka, Kei ;
Fujimoto, Nobukazu ;
Yokoyama, Toshihide ;
Gemba, Kenichi ;
Tsuda, Takeshi ;
Nakagawa, Hideyuki ;
Ono, Hirotaka ;
Shimizu, Tetsuo ;
Nakamura, Morio ;
Kusumoto, Sojiro ;
Hayashi, Ryuji ;
Shirasaki, Hiroki ;
Ochi, Nobuaki ;
Aoe, Keisuke ;
Kanaji, Nobuhiro ;
Kashiwabara, Kosuke ;
Inoue, Hiroshi ;
Seki, Nobuhiko .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[49]   Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer [J].
Mornex, Francoise ;
Peignaux, Karine ;
Germain, Thierry ;
Wautot, Virginie ;
Chouaki, Nadia ;
Bourayou, Nawel ;
Tourani, Jean-Marc .
LUNG CANCER, 2013, 80 (01) :68-74
[50]   Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study [J].
Zatloukal, P ;
Petruzelka, L ;
Zemanova, M ;
Havel, L ;
Janku, F ;
Judas, L ;
Kubik, A ;
Krepela, E ;
Fiala, P ;
Pecen, L .
LUNG CANCER, 2004, 46 (01) :87-98